Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE

Clin Nucl Med. 2022 Nov 1;47(11):e692-e695. doi: 10.1097/RLU.0000000000004307. Epub 2022 Jun 11.

Abstract

A 76-year-old woman affected by pancreatic neuroendocrine tumor previously subjected to surgery with progressive liver disease and a concomitant mild symptomatic meningioma of the left pontocerebellar angle underwent 4 cycles of peptide receptor radionuclide therapy with 177 Lu-DOTATATE. A prophylactic therapy with corticosteroids was carried out before each treatment cycle, and the neurosurgery unit was alerted in case of cerebral edema and related neurologic symptoms. A 68 Ga-DOTATOC PET/CT scan performed after the completion of the 4 cycles' treatment documented a hepatic partial response and a substantial stability of the brain mass. No neurological complications occurred during treatment and follow-up.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Female
  • Humans
  • Intestinal Neoplasms*
  • Lutetium
  • Meningeal Neoplasms* / diagnostic imaging
  • Meningeal Neoplasms* / radiotherapy
  • Meningioma* / diagnostic imaging
  • Meningioma* / radiotherapy
  • Neuroendocrine Tumors* / pathology
  • Neuroendocrine Tumors* / radiotherapy
  • Octreotide / therapeutic use
  • Organometallic Compounds* / therapeutic use
  • Pancreatic Neoplasms* / radiotherapy
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radioisotopes
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Receptors, Peptide
  • Stomach Neoplasms

Substances

  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Peptide
  • copper dotatate CU-64
  • Lutetium
  • Lutetium-177
  • Octreotide

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor